Welcome to our dedicated page for Alnylam Pharmaceuticals news (Ticker: ALNY), a resource for investors and traders seeking the latest updates and insights on Alnylam Pharmaceuticals stock.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) regularly issues news on its RNA interference (RNAi) therapeutics, commercial performance, pipeline progress, and corporate developments. As a company that has led the RNAi field from discovery to approved medicines, its announcements often highlight data from pivotal trials, regulatory milestones, and updates on marketed products such as AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
Investors following ALNY news can expect detailed coverage of clinical results across multiple therapeutic areas, including transthyretin‑mediated amyloidosis (ATTR), hypertension, bleeding disorders, neurological diseases, and metabolic conditions. Recent releases have described post hoc analyses from the HELIOS‑B Phase 3 study of AMVUTTRA in ATTR‑CM and hATTR‑PN, showing effects on gastrointestinal events, cardiac structure and function, and renal outcomes, as well as broader safety and efficacy profiles.
Alnylam’s news flow also includes financial and strategic updates. The company reports quarterly and annual net product revenues, trends in its TTR and rare disease franchises, and guidance associated with frameworks such as its Alnylam P5x25 and Alnylam 2030 strategies. Filings and press releases have discussed convertible senior notes, a revolving credit facility, and partial repurchases of outstanding debt, providing context on capital structure and liquidity.
Operational and manufacturing developments are another key news theme. Alnylam has announced expansion of its Norton, Massachusetts siRNA manufacturing facility and the integration of its siRELIS enzymatic ligation platform, which has been accepted into the FDA’s Emerging Technology Program. Corporate governance items, such as changes to the Board of Directors and executive responsibilities, are also disclosed. For anyone tracking ALNY, this news stream offers insight into clinical milestones, commercial execution, manufacturing scale‑up, and strategic direction in RNAi therapeutics.
Alnylam Pharmaceuticals reported positive topline results from its HELIOS-B Phase 3 study for vutrisiran, an RNAi therapeutic for ATTR amyloidosis with cardiomyopathy (ATTR-CM).
Statistically significant reductions in all-cause mortality and recurrent cardiovascular events were observed in both the overall population and monotherapy population. Specifically, the study showed a 28% reduction in the overall population and a 33% reduction in the monotherapy population.
Secondary endpoints also demonstrated significant improvements, including a 36% reduction in all-cause mortality in the overall population and a 35% reduction in the monotherapy population. Other key measures such as the 6-minute walk test, Kansas City Cardiomyopathy Questionnaire, and NYHA Class also showed clinical benefits.
The study confirmed vutrisiran's safety profile, with adverse events comparable between the vutrisiran and placebo groups. Alnylam plans to file a U.S. Supplemental New Drug Application and proceed with global regulatory submissions.
Alnylam Pharmaceuticals, Inc. issued its 2023 Corporate Responsibility Report, showcasing its commitment to environmental sustainability, patient access, and health equity. The report includes new data on environmental impact, expanded partnerships for diversity and inclusion in clinical trials, and the extension of the Alnylam Challengers global health equity initiative. Additionally, the report discloses employee demographic data and results of a pay equity analysis.
Alnylam Pharmaceuticals reported strong first quarter 2024 financial results with Global Net Product Revenues of $365 million, reflecting a 32% Year-Over-Year Growth. The company achieved positive results in the Zilebesiran Hypertension Program, initiated Phase 2 studies, and remains on track to report Topline Results from Vutrisiran's Phase 3 Study. Alnylam reiterated its 2024 Financial Guidance with expected combined Net Product Revenues of $1,400 million to $1,500 million.
Medison Pharma and Alnylam Pharmaceuticals have announced an expansion of their partnership to commercialize RNAi therapeutics in additional markets, including LATAM and APAC, to provide innovative therapies to patients across the globe. This partnership aims to accelerate access to Alnylam's life-saving therapies in multiple regions under one global alliance.
FAQ
What is the current stock price of Alnylam Pharmaceuticals (ALNY)?
What is the market cap of Alnylam Pharmaceuticals (ALNY)?
